Install
- 6,371articles · 30d
- 7+ hour agolatest article
- Aug 15, 2026earliest in window
- 91%with images
- 271avg words
- Economy, Business & Finance 2,999
- Finance & Business 2,325
- News 1,948
- Business & Industrial 774
- Politics 622
- Finance 561
- Science & Technology 439
- Arts, Culture, Entertainment & Media 429
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Sweden immigration restrictions spark healthcare concerns
5+ day, 30+ min ago (714+ words) TROLLHATTAN, Sweden — A dramatic tightening of Sweden's migration policy has sparked concern in a healthcare sector that is ever more dependent on immigrants, professionals warned ahead of a general election on Sunday. "I'm the only one born in Sweden here…...
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
5+ day, 1+ hour ago (190+ words) Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company…...
Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026
5+ day, 5+ hour ago (83+ words) "STIMULAN® gained MDR certification earlier this year and is the only calcium matrix that can be mixed with a combination of antibiotics, resolve infection and reduce the need for secondary surgery.” Details of Biocomposites’ symposium at the EBJIS-MSIS Conference are…...
Inventiva to Present Multiple Abstracts at Paris MASH 2026
5+ day, 16+ hour ago (847+ words) The Manila Times - Phase 1 and Phase 2 clinical data showed lanifibranor improves metabolic profile and cardiovascular risk factors in patients with MASH with or without type 2 diabetes - Preclinical data further characterize lanifibranor’s balanced pan-PPAR pharmacology and support a differentiated fluid and…...
‘Secondhand smoke causes 1.7M deaths’
5+ day, 20+ hour ago (279+ words) Tobacco remains a leading cause of disease globally, the study said, noting many “non-smokers exposed to secondhand smoke” were among the estimated total of 8 million people who died in 2023 of smoking-related illnesses. “Exposure to secondhand smoke is a globally recognized…...
Spokane Dermatologist Dr. Wm. Philip Werschler Surpasses 3,000 Research Citations
5+ day, 20+ hour ago (271+ words) The board-certified dermatologist and longtime clinical trial investigator has more than 140 publications and more than 75,000 reads on ResearchGate, where comparative analytics place him above 94% of dermatology researchers ResearchGate's comparative analytics place Werschler above 94% of dermatology researchers on the platform by…...
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
6+ day, 1+ hour ago (723+ words) The Manila Times Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and…...
New Multi-Site Validation Study Published by Panakeia Reinforces Scalability of AI Multi-Omics Platform
6+ day, 5+ hour ago (143+ words) Study confirms diagnostic-grade performance of PANProfiler Breast (ER, PR, HER2) from routine brightfield images; establishing the technology as a scalable foundation for oncology across multiple cancer types and biomarkers These findings build upon the platform's established success in colorectal cancer (PANProfiler…...
From Smart Massage to Proactive Wellness: SKG Expands Its Wearable Health Portfolio at IFA 2026
6+ day, 4+ hour ago (283+ words) BERLIN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SKG Health is showcasing an expanded portfolio of wearable health products at IFA 2026, highlighting its move from portable massage into recovery, training support and proactive health monitoring. International media and visitors from Germany and across Europe…...
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
6+ day, 6+ hour ago (302+ words) GRWD0715, a first-in-class oral ERAP1 inhibitor to treat CD8+ T cell-mediated autoimmunity, has now been dosed in participants with axSpA after the completion of the SAD portion of its Phase 1/2 study (EAST-1) in healthy volunteers, demonstrating dose-proportional PK, clear evidence of ERAP1 target engagement,…...